protease inhibitors

ApprovedSmall molecule

Tibotec Pharmaceuticals, Ireland

protease inhibitors is one of 83 small molecule programs targeting Atrophy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtrophyActive, not recruiting

ImmunodeficiencyActive, not recruiting

AtrophyApproved

Active, not recruiting

ImmunodeficiencyPhase 2

Active, not recruiting

Competition

Competitive Landscape

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Cabenuva

GSK

Phase 3

6 2

Sovaldi

Gilead

Phase 3

2 3

Farxiga

AstraZeneca

Phase 3

1 4

Viread

Gilead

Phase 3

1 5

Repatha

Amgen

Phase 3

1 6

Emtriva

Gilead

Phase 3

1 7

Edurant Ped

WWim Janssens

Phase 3

8 8

Retrovir

BBp Consulting, Inc

Phase 3

6 9

Vemlidy

Prezista

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrophy1 trial

Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 4·NCT00122655·100 enrolled

Immunodeficiency1 trial

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00128830·211 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for protease inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — protease inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for protease inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tibotec Pharmaceuticals, Ireland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Tibotec Pharmaceuticals, Ireland

protease inhibitors

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrophy1 trial

Immunodeficiency1 trial

References

Drug Info

Quick Facts

Related News